F X Jiang1, E Georges-Labouesse, L C Harrison. 1. Autoimmunity and Transplantation Division, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Australia.
Abstract
BACKGROUND: The ability to manipulate the development of pancreatic insulin-producing beta cells has implications for the treatment of type 1 diabetes. Previously, we found that laminin-1, a basement membrane trimeric glycoprotein, promotes beta-cell differentiation. We have investigated the mechanism of this effect, using agents that block the receptors for laminin-1, alpha6 integrin, and alpha-dystroglycan (alpha-DG). MATERIALS AND METHODS: Dissociated cells from 13.5-day postcoitum (dpc) fetal mouse pancreas were cultured for 4 days with laminin-1, with and without monoclonal antibodies and other agents known to block integrins or alpha-DG. Fetuses fixed in Bouin's solution or fetal pancreas cells fixed in 4% paraformaldehyde were processed for routine histology and for immunohistology to detect hormone expression and bromodeoxyuridine (BrdU) uptake. RESULTS: Blocking the binding of laminin-1 to alpha6 integrin with a monoclonal antibody, GoH3, abolished cell proliferation (BrdU uptake) and doubled the number of beta cells. Inhibition of molecules involved in alpha6 integrin signaling (phosphotidylinositol 3-kinase, F-actin, or mitogen-activated protein kinase) had a similar effect. Nevertheless, beta cells appeared to develop normally in alpha6 integrin-deficient fetuses. Blocking the binding of laminin-1 to alpha-DG with a monoclonal antibody, IIH6, dramatically decreased the number of beta cells. Heparin, also known to inhibit laminin-1 binding to alpha-DG, had a similar effect. In the presence of heparin, the increase in beta cells in response to blocking alpha integrin with GoH3 was abolished. CONCLUSIONS: These findings reveal an interplay between alpha6 integrin and alpha-DG to regulate laminin-1-induced beta-cell development. Laminin-I had a dominant effect via alpha-DG to promote cell survival and beta-cell differentiation, which was modestly inhibited by alpha6 signaling.
BACKGROUND: The ability to manipulate the development of pancreatic insulin-producing beta cells has implications for the treatment of type 1 diabetes. Previously, we found that laminin-1, a basement membrane trimeric glycoprotein, promotes beta-cell differentiation. We have investigated the mechanism of this effect, using agents that block the receptors for laminin-1, alpha6 integrin, and alpha-dystroglycan (alpha-DG). MATERIALS AND METHODS: Dissociated cells from 13.5-day postcoitum (dpc) fetal mouse pancreas were cultured for 4 days with laminin-1, with and without monoclonal antibodies and other agents known to block integrins or alpha-DG. Fetuses fixed in Bouin's solution or fetal pancreas cells fixed in 4% paraformaldehyde were processed for routine histology and for immunohistology to detect hormone expression and bromodeoxyuridine (BrdU) uptake. RESULTS: Blocking the binding of laminin-1 to alpha6 integrin with a monoclonal antibody, GoH3, abolished cell proliferation (BrdU uptake) and doubled the number of beta cells. Inhibition of molecules involved in alpha6 integrin signaling (phosphotidylinositol 3-kinase, F-actin, or mitogen-activated protein kinase) had a similar effect. Nevertheless, beta cells appeared to develop normally in alpha6 integrin-deficient fetuses. Blocking the binding of laminin-1 to alpha-DG with a monoclonal antibody, IIH6, dramatically decreased the number of beta cells. Heparin, also known to inhibit laminin-1 binding to alpha-DG, had a similar effect. In the presence of heparin, the increase in beta cells in response to blocking alpha integrin with GoH3 was abolished. CONCLUSIONS: These findings reveal an interplay between alpha6 integrin and alpha-DG to regulate laminin-1-induced beta-cell development. Laminin-I had a dominant effect via alpha-DG to promote cell survival and beta-cell differentiation, which was modestly inhibited by alpha6 signaling.
Authors: I Virtanen; M Banerjee; J Palgi; O Korsgren; A Lukinius; L-E Thornell; Y Kikkawa; K Sekiguchi; M Hukkanen; Y T Konttinen; T Otonkoski Journal: Diabetologia Date: 2008-04-26 Impact factor: 10.122
Authors: John R B Perry; Benjamin F Voight; Loïc Yengo; Najaf Amin; Josée Dupuis; Martha Ganser; Harald Grallert; Pau Navarro; Man Li; Lu Qi; Valgerdur Steinthorsdottir; Robert A Scott; Peter Almgren; Dan E Arking; Yurii Aulchenko; Beverley Balkau; Rafn Benediktsson; Richard N Bergman; Eric Boerwinkle; Lori Bonnycastle; Noël P Burtt; Harry Campbell; Guillaume Charpentier; Francis S Collins; Christian Gieger; Todd Green; Samy Hadjadj; Andrew T Hattersley; Christian Herder; Albert Hofman; Andrew D Johnson; Anna Kottgen; Peter Kraft; Yann Labrune; Claudia Langenberg; Alisa K Manning; Karen L Mohlke; Andrew P Morris; Ben Oostra; James Pankow; Ann-Kristin Petersen; Peter P Pramstaller; Inga Prokopenko; Wolfgang Rathmann; William Rayner; Michael Roden; Igor Rudan; Denis Rybin; Laura J Scott; Gunnar Sigurdsson; Rob Sladek; Gudmar Thorleifsson; Unnur Thorsteinsdottir; Jaakko Tuomilehto; Andre G Uitterlinden; Sidonie Vivequin; Michael N Weedon; Alan F Wright; Frank B Hu; Thomas Illig; Linda Kao; James B Meigs; James F Wilson; Kari Stefansson; Cornelia van Duijn; David Altschuler; Andrew D Morris; Michael Boehnke; Mark I McCarthy; Philippe Froguel; Colin N A Palmer; Nicholas J Wareham; Leif Groop; Timothy M Frayling; Stéphane Cauchi Journal: PLoS Genet Date: 2012-05-31 Impact factor: 5.917
Authors: Maqsood Ahmed; Leandro N Marziali; Ernest Arenas; M Laura Feltri; Charles Ffrench-Constant Journal: Development Date: 2019-08-29 Impact factor: 6.868